KR102410069B1 - Ror 감마의 조절제로서의 화합물 - Google Patents

Ror 감마의 조절제로서의 화합물 Download PDF

Info

Publication number
KR102410069B1
KR102410069B1 KR1020167031654A KR20167031654A KR102410069B1 KR 102410069 B1 KR102410069 B1 KR 102410069B1 KR 1020167031654 A KR1020167031654 A KR 1020167031654A KR 20167031654 A KR20167031654 A KR 20167031654A KR 102410069 B1 KR102410069 B1 KR 102410069B1
Authority
KR
South Korea
Prior art keywords
cycloalkyl
alkyl
mmol
compound
optionally substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020167031654A
Other languages
English (en)
Korean (ko)
Other versions
KR20160142396A (ko
Inventor
요한나 바코니
스티븐 리차드 브루넷
델펀 콜린
로버트 오웬 휴즈
샹 리
솽 량
로버트 시블리
마이클 로버트 터너
리펜 우
창 장
Original Assignee
베링거 인겔하임 인터내셔날 게엠베하
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 베링거 인겔하임 인터내셔날 게엠베하 filed Critical 베링거 인겔하임 인터내셔날 게엠베하
Priority to KR1020207010364A priority Critical patent/KR102410076B1/ko
Publication of KR20160142396A publication Critical patent/KR20160142396A/ko
Application granted granted Critical
Publication of KR102410069B1 publication Critical patent/KR102410069B1/ko
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D475/00—Heterocyclic compounds containing pteridine ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D475/00—Heterocyclic compounds containing pteridine ring systems
    • C07D475/06—Heterocyclic compounds containing pteridine ring systems with a nitrogen atom directly attached in position 4
    • C07D475/10—Heterocyclic compounds containing pteridine ring systems with a nitrogen atom directly attached in position 4 with an aromatic or hetero-aromatic ring directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • Y10S514/825—
    • Y10S514/863—

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Vascular Medicine (AREA)
  • Otolaryngology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020167031654A 2014-04-14 2015-04-10 Ror 감마의 조절제로서의 화합물 Expired - Fee Related KR102410069B1 (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020207010364A KR102410076B1 (ko) 2014-04-14 2015-04-10 Ror 감마의 조절제로서의 화합물

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461979231P 2014-04-14 2014-04-14
US61/979,231 2014-04-14
PCT/US2015/025328 WO2015160654A1 (en) 2014-04-14 2015-04-10 Compounds as modulators of ror gamma

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020207010364A Division KR102410076B1 (ko) 2014-04-14 2015-04-10 Ror 감마의 조절제로서의 화합물

Publications (2)

Publication Number Publication Date
KR20160142396A KR20160142396A (ko) 2016-12-12
KR102410069B1 true KR102410069B1 (ko) 2022-06-20

Family

ID=52998264

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020167031654A Expired - Fee Related KR102410069B1 (ko) 2014-04-14 2015-04-10 Ror 감마의 조절제로서의 화합물
KR1020207010364A Expired - Fee Related KR102410076B1 (ko) 2014-04-14 2015-04-10 Ror 감마의 조절제로서의 화합물

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020207010364A Expired - Fee Related KR102410076B1 (ko) 2014-04-14 2015-04-10 Ror 감마의 조절제로서의 화합물

Country Status (35)

Country Link
US (5) US9242989B2 (enExample)
EP (2) EP3131902B1 (enExample)
JP (2) JP6282759B2 (enExample)
KR (2) KR102410069B1 (enExample)
CN (3) CN107266450B (enExample)
AP (1) AP2016009403A0 (enExample)
AR (2) AR100058A1 (enExample)
AU (2) AU2015247983B2 (enExample)
BR (2) BR122020020657B1 (enExample)
CA (1) CA2944787C (enExample)
CL (1) CL2016002421A1 (enExample)
CY (1) CY1122012T1 (enExample)
DK (1) DK3131902T3 (enExample)
EA (2) EA035063B1 (enExample)
ES (1) ES2744299T3 (enExample)
HR (1) HRP20191579T1 (enExample)
HU (1) HUE045847T2 (enExample)
IL (2) IL247419B (enExample)
LT (1) LT3131902T (enExample)
MA (1) MA46373A (enExample)
ME (1) ME03513B (enExample)
MX (1) MX370780B (enExample)
MY (1) MY182834A (enExample)
NZ (1) NZ723530A (enExample)
PE (2) PE20211002A1 (enExample)
PH (2) PH12016502019B1 (enExample)
PL (1) PL3131902T3 (enExample)
PT (1) PT3131902T (enExample)
RS (1) RS59170B1 (enExample)
SG (1) SG11201608537SA (enExample)
SI (1) SI3131902T1 (enExample)
TW (2) TWI652268B (enExample)
UA (2) UA121255C2 (enExample)
UY (1) UY36077A (enExample)
WO (1) WO2015160654A1 (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR122020020657B1 (pt) * 2014-04-14 2022-12-20 Boehringer Ingelheim International Gmbh Compostos, composição farmacêutica e seus usos como moduladores de ror gama
FR3030518B1 (fr) * 2014-12-19 2018-03-23 Galderma Research & Development Derives sulfonamides en tant qu'agonistes inverses du recepteur gamma orphelin associe aux retinoides ror gamma (t)
KR102702236B1 (ko) 2015-05-15 2024-09-04 오리진 온콜로지 리미티드 Ror 감마 조절제로서의 치환된 테트라하이드로퀴놀리논 화합물
US10450314B2 (en) 2015-10-01 2019-10-22 Boehringer Ingelheim International Gmbh Pteridine derivatives as modulators of ROR gamma
KR101947976B1 (ko) 2015-12-15 2019-02-13 아스트라제네카 아베 이소인돌 화합물
EP3405470B1 (en) * 2016-01-20 2020-07-15 Boehringer Ingelheim International GmbH Pyrazinedihydropyrimidinone or pyridazinedihydropyrimidinone compounds as modulators of ror gamma
AR110481A1 (es) 2016-12-05 2019-04-03 Lead Pharma Holding Bv MODULADORES DE ROR g (RORg)
US20200031753A1 (en) 2017-04-06 2020-01-30 Boehringer Ingelheim International Gmbh Cyclopropyl alkyl amines and process for their preparation
EP3638661A1 (en) 2017-06-14 2020-04-22 Astrazeneca AB 2,3-dihydroisoindole-1-carboxamides useful as ror-gamma modulators
CN109206346A (zh) * 2017-07-01 2019-01-15 复旦大学 叔胺类衍生物或其盐及其制备方法和用途
CN107903263B (zh) * 2017-12-28 2019-11-12 山东铂源药业有限公司 一种帕布昔利布中间体的合成方法
SMT202300212T1 (it) 2018-05-03 2023-09-06 Shanghai hengrui pharmaceutical co ltd Derivati di benzimidazolo come modulatori del recettore gamma orfano correlato al retinoide (rory) e usi farmaceutici di essi
US20210395185A1 (en) 2018-10-18 2021-12-23 Boehringer Ingelheim International Gmbh Scalable synthesis of optically active 1-cyclopropylalkyl-1-amines
WO2021061803A1 (en) 2019-09-23 2021-04-01 Nanjing Zhengxiang Pharmaceuticals Co., Ltd. Phosphodiesterase inhibitors and use
US20230014730A1 (en) 2019-09-23 2023-01-19 Nanjing Zhengxiang Pharmaceuticals Co., Ltd. Phosphodiesterase inhibitors and use
BR112022008293A2 (pt) 2019-10-31 2022-07-26 Jiangsu Hengrui Medicine Co Sal de adição de ácido de regulador de ror?, composições farmacêuticas, uso dos mesmos e métodos para preparar forma cristalina e composição farmacêutica
WO2022106548A1 (en) 2020-11-19 2022-05-27 Boehringer Ingelheim International Gmbh Solid forms of a ror gamma inhibitor
WO2022106549A1 (en) 2020-11-19 2022-05-27 Boehringer Ingelheim International Gmbh Crystalline salts of a ror gamma inhibitor
WO2022106547A1 (en) 2020-11-19 2022-05-27 Boehringer Ingelheim International Gmbh Process for synthesising a ror gamma inhibitor
WO2022106550A1 (en) 2020-11-19 2022-05-27 Boehringer Ingelheim International Gmbh Crystalline polymorphic form of a ror gamma inhibitor
WO2022106551A1 (en) 2020-11-19 2022-05-27 Boehringer Ingelheim International Gmbh Co-crystals of a ror gamma inhibitor
CN117003757A (zh) * 2022-05-07 2023-11-07 苏州浦合医药科技有限公司 取代的双环杂芳基化合物作为usp1抑制剂
WO2023232870A1 (en) 2022-05-31 2023-12-07 Immunic Ag Rorg/rorgt modulators for the treatment of virus infections like covid-19
CN116178279A (zh) * 2023-03-15 2023-05-30 上海药坦药物研究开发有限公司 一种5-溴-4-环丙基-6-甲氧基嘧啶及其中间体的制备方法
AU2024267864A1 (en) * 2023-05-09 2025-11-06 11949098 Canada Inc. Inverse agonists of rar related orphan receptors (rors)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003024966A1 (en) 2001-08-14 2003-03-27 Astrazeneca Ab Pteridinone derivatives as modulators of chemokine receptor activity

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009022185A2 (en) * 2007-08-16 2009-02-19 Astrazeneca Ab 6, 6-fused heterocycles, their pharmaceutical compositions and methos of use
PE20110854A1 (es) 2008-09-26 2011-12-23 Boehringer Ingelheim Int DERIVADOS DE 1-FENIL-1H-PIRAZOLO[3,4-c]PIRIDINA-4-CARBONILAMINA COMO ANTAGONISTAS DE LOS RECEPTORES CCR1
AP2012006204A0 (en) 2009-10-21 2012-04-30 Boehringer Ingelheim Int Indazole and pyrazolopyridine compounds as CCR1 receptor antagonists.
BR112013030894A2 (pt) * 2011-06-01 2016-08-16 Janus Biotherapeutics Inc moduladores do sistema imune
CN106008511B (zh) * 2012-05-14 2018-08-14 华东理工大学 蝶啶酮衍生物及其作为egfr、blk、flt3抑制剂的应用
BR122020020657B1 (pt) * 2014-04-14 2022-12-20 Boehringer Ingelheim International Gmbh Compostos, composição farmacêutica e seus usos como moduladores de ror gama
US10450314B2 (en) * 2015-10-01 2019-10-22 Boehringer Ingelheim International Gmbh Pteridine derivatives as modulators of ROR gamma
EP3405470B1 (en) * 2016-01-20 2020-07-15 Boehringer Ingelheim International GmbH Pyrazinedihydropyrimidinone or pyridazinedihydropyrimidinone compounds as modulators of ror gamma

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003024966A1 (en) 2001-08-14 2003-03-27 Astrazeneca Ab Pteridinone derivatives as modulators of chemokine receptor activity

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 19, 4092-4096 (2009)
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 23(2), 532-536 (2013)

Also Published As

Publication number Publication date
AU2015247983A1 (en) 2016-09-08
PE20211002A1 (es) 2021-06-01
BR112016021962A2 (pt) 2023-01-20
MX370780B (es) 2020-01-03
US20160075706A1 (en) 2016-03-17
EP3418280B1 (en) 2023-07-12
AR100058A1 (es) 2016-09-07
JP2017511357A (ja) 2017-04-20
US9242989B2 (en) 2016-01-26
HK1244800A1 (zh) 2018-08-17
CA2944787A1 (en) 2015-10-22
CY1122012T1 (el) 2020-10-14
UY36077A (es) 2015-10-30
CA2944787C (en) 2023-03-14
US20170008894A1 (en) 2017-01-12
HRP20191579T1 (hr) 2019-11-29
IL247419B (en) 2019-03-31
IL263878A (en) 2019-01-31
JP2018065874A (ja) 2018-04-26
PH12016502019B1 (en) 2020-10-23
PL3131902T3 (pl) 2019-11-29
CN107266450B (zh) 2020-07-24
JP6282759B2 (ja) 2018-02-21
LT3131902T (lt) 2019-09-25
MY182834A (en) 2021-02-05
CN107266450A (zh) 2017-10-20
JP6463855B2 (ja) 2019-02-06
IL263878B (en) 2019-11-28
TW201625622A (zh) 2016-07-16
ES2744299T3 (es) 2020-02-24
US20180022749A1 (en) 2018-01-25
PH12016502019A1 (en) 2017-01-09
TWI655192B (zh) 2019-04-01
PH12020500252A1 (en) 2021-07-26
CN107266454A (zh) 2017-10-20
HK1244801A1 (zh) 2018-08-17
CN106132965A (zh) 2016-11-16
TWI652268B (zh) 2019-03-01
AU2015247983B2 (en) 2019-05-16
EA035063B1 (ru) 2020-04-23
EA031351B1 (ru) 2018-12-28
KR20200040917A (ko) 2020-04-20
KR20160142396A (ko) 2016-12-12
EA201890329A1 (ru) 2018-07-31
UA121255C2 (uk) 2020-04-27
AU2019203027B2 (en) 2020-07-09
EP3418280A1 (en) 2018-12-26
HUE045847T2 (hu) 2020-01-28
EP3131902B1 (en) 2019-06-12
MA46373A (fr) 2019-08-07
SI3131902T1 (sl) 2019-10-30
MX2016013342A (es) 2017-01-26
US9598415B2 (en) 2017-03-21
NZ723530A (en) 2023-05-26
TW201841915A (zh) 2018-12-01
ME03513B (me) 2020-04-20
WO2015160654A1 (en) 2015-10-22
PE20161572A1 (es) 2017-02-01
CN106132965B (zh) 2020-02-07
AP2016009403A0 (en) 2016-08-31
DK3131902T3 (da) 2019-09-02
EP3131902A1 (en) 2017-02-22
BR112016021962B1 (pt) 2022-12-13
AR119454A2 (es) 2021-12-22
US20150291607A1 (en) 2015-10-15
EA201691978A1 (ru) 2017-02-28
CN107266454B (zh) 2019-08-09
AU2019203027A1 (en) 2019-05-23
CL2016002421A1 (es) 2017-03-24
UA120094C2 (uk) 2019-10-10
SG11201608537SA (en) 2016-11-29
RS59170B1 (sr) 2019-10-31
PT3131902T (pt) 2019-09-17
BR122020020657B1 (pt) 2022-12-20
KR102410076B1 (ko) 2022-06-22
US20190002465A1 (en) 2019-01-03

Similar Documents

Publication Publication Date Title
KR102410076B1 (ko) Ror 감마의 조절제로서의 화합물
JP6192836B2 (ja) Ｒｏｒｃモジュレーターとしてのアザインドール化合物
EP3041821B1 (en) Bicylic compounds as modulators of rorgamma
JP2019507120A (ja) ガンマのモジュレータとしての化合物
HK1227037A1 (en) Compounds as modulators of ror gamma
HK1244800B (en) Compounds as modulators of ror gamma
HK1227037B (en) Compounds as modulators of ror gamma
HK1244801B (en) Compounds as modulators of ror gamma
TW201838997A (zh) 作為RORγ調節劑之化合物

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A107 Divisional application of patent
A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A17-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20250615

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

H13 Ip right lapsed

Free format text: ST27 STATUS EVENT CODE: N-4-6-H10-H13-OTH-PC1903 (AS PROVIDED BY THE NATIONAL OFFICE); TERMINATION CATEGORY : DEFAULT_OF_REGISTRATION_FEE

Effective date: 20250615

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20250615